Ascendis Pharma Growth Disorders A/s

This study tested a once-weekly injection called TransCon CNP in 84 children aged 2 to 11 with achondroplasia, the most common form of dwarfism. The goal was to see if it safely increases growth rate over a year compared to a placebo. After the first year, all children could rece…